Propanc Biopharma, Inc. (PPCB)

0.0008 -0.0002 (-20.00%) At close: 03:58PM EDT

Propanc Biopharma, Inc.

302, 6 Butler Street
Camberwell, VIC 3124
Australia
61 3 9882 0780
https://www.propanc.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1

Key executives

Name	Title	Pay	Exercised	Year born
Mr. James Nathanielsz	Executive Chairman, CEO, CFO, Treasurer & Secretary	430.28k	N/A	1974
Dr. Julian Norman Kenyon ChB, M.D., MB	Chief Scientific Officer, CTO & Director	35.99k	N/A	1948
Prof. Klaus Kutz	Chief Medical Officer & Member of Scientific Advisory Board	18.23k	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Corporate governance

Propanc Biopharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.